Scientists Test Coated Liposomes for Oral Tirzepatide
Sofia Reyes · Health & Nutrition Writer
November 17, 2026 · 1 min read
A new formulation study published in Int J Pharm X looks at whether polydopamine coated liposomes could help tirzepatide survive passage through the digestive tract, according to the study listing on PubMed. Tirzepatide is currently available only as an injectable, approved medication for weight management and type 2 diabetes. Like most peptides, it breaks down quickly when exposed to stomach acid and digestive enzymes, which is why an oral version has been a long standing goal for formulation chemists.
The approach described in the title uses polydopamine, a material known for its ability to form protective coatings, as a shell around liposomes carrying the peptide. In theory, this kind of coating could shield the drug from gastrointestinal breakdown long enough for it to reach the bloodstream through the gut lining. The listing itself does not provide the full methods or results, so it is unclear from the available text whether this work was tested in cells, in animals, or in some other model system.
This is formulation and delivery research, not a clinical trial, and it says nothing about safety or effectiveness in people. Any oral delivery platform like this would need extensive additional testing before it could be considered an alternative to injectable tirzepatide.
This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.
Ready to explore peptides?
Browse every compound profile or work out your dose with the reconstitution calculator.


